FDC LTD. - 531599 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Dear Sir/Madam, Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform that the Company has scheduled an Earnings Conference Call for the quarter and year ended March 31, 2022 with Analyst / Investors through Audio Conferencing on Friday, May 27, 2022 at 03:00 p.m. (IST). FDC LTD. - 531599 - Corporate Action-Updates on Buy back
Completion of Extinguishment/destruction of a total of 29,00,000 Equity Shares of the face value of Rs. 1 each. FDC LTD. - 531599 - Board Meeting Intimation for Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2022.
FDC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, May 25, 2022, at Mumbai, to interalia, consider and approve the Audited Financial Results of the Company for the quarter and Financial Year ended March 31, 2022. Further, in accordance with Code of Conduct adopted by the Company, SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 and vide our intimation letter dated March 28, 2022, the Trading Window of the Company has been closed for all the Directors and Designated Persons from Friday, April 01, 2022, till 48 hours after the declaration of Audited Financial Results for the quarter and year ended March 31, 2022. FDC LTD. - 531599 - Announcement under Regulation 30 (LODR)-Public Announcement-Buyback of Shares
Post Offer Public Announcement in terms of Regulation 24(vi) of the Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 in respect to the Buyback offer of 29,00,000 equity shares by FDC Limited
Glenmark launches fixed-dose combination medication for diabetic patients
Glenmark Pharmaceuticals on Monday said it has launched a novel fixed-dose combination (FDC) of Teneligliptin, with Pioglitazone in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement. Diabetes is a key area of focus for Glenmark; a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients, Glenmark Pharmaceuticals Group Vice President & Head, India Formulations Alok Malik said. Glenmark claimed it is the "first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which is approved by the DCGI (Drug Controller General of India)" "This fixed-dose combination will be FDC LTD. - 531599 - Public Notice Pertaining To Buyback Of Equity Shares By The Company
Please find enclosed the Public Notice published in the newspapers on Tuesday, April 19, 2022. FDC LTD. - 531599 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0101 Name of the Signatory :- Varsharani KatreDesignation :- Company Secretary and Compliance Officer FDC LTD. - 531599 - Compliance Certificate Under Regulation 40 (9) & 40 (10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Please find enclosed herewith the Certificate under Regulation 40(9) of the Listing Regulations for the year ended on March 31, 2022, received from M/s. Sanjay Dholakia & Associates, Company Secretaries in Practice dated April 15, 2022. Kindly take the same on record. FDC LTD. - 531599 - Compliance Certificate For The Year Ended March 31, 2022
This is to certify that pursuant to Regulation 7 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, FDC Limited has complied with the requirements pursuant to Regulation 7 (2) by ensuring that all the activities in relation to both, Physical and Electronic, share transfer facilities i.e. Dematerialization and Rematerialization are maintained through it's Registrar and Share Transfer Agent, M/s. Link Intime India Pvt. Ltd., who is registered with the Board (SEBI), under registration No INR000004058 for the Half year ended March 31, 2022. FDC LTD. - 531599 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed the certificate issued by the Registrar and Share Transfer Agent of the Company i.e Link Intime India Pvt. Ltd., regarding the details of the securities dematerialized/rematerialized during the quarter ended on March 31, 2022 as required under regulation 74 (5) of the SEBI (Depositories and Participants) Regulation, 2018.